Specialty chemicals manufacturer Rossari Biotech Ltd witnessed a sharp decline in its stock price, falling over 3% to ₹778.25 during Tuesday’s trading session. The fall comes after the company reported a weaker-than-expected Q3 FY25 performance.
Key Highlights of Q3 FY25 Results:
- Net Profit: Declined 7.6% YoY to ₹31.7 crore, compared to ₹34.3 crore in Q3 FY24.
- Revenue from Operations: Increased 10.6% YoY to ₹512.7 crore, compared to ₹463.7 crore in the same quarter last year.
- EBITDA: Increased 1.9% to ₹64.7 crore, compared to ₹63.5 crore in the year-ago quarter.
- EBITDA Margin: Declined to 12.6% from 13.7% in Q3 FY24.
The company’s profitability was impacted despite revenue growth, primarily due to a contraction in EBITDA margins, which stood at 12.6% versus 13.7% a year ago. Rising input costs and lower operational efficiency were key contributors to the margin squeeze.
The weak Q3 performance has dented investor sentiment, leading to a sell-off in the stock. Market experts will closely watch Rossari Biotech’s plans to address margin pressures in the coming quarters.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions.
